StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BTIG Affirms Mylan (MYL) at 'Buy'; Generic EpiPen Highlights Challenges to U.S. Healthcare System
August 29, 2016 2:22 PM
BTIG affirms Mylan (Nasdaq: MYL) with a Buy rating and $60 price target as the company moves to release a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Congress Letter to FDA Questioning Generic EpiPen Alternatives (MYL) (TEVA) (ADMP) (IPXL)
August 29, 2016 1:15 PM
Generic EpiPen Pricing Parity and Less than 1% Share Supports $10 Adamis (ADMP) Target Price - Maxim Group
August 29, 2016 1:04 PM
Generic EpiPen to Hit Mylan (MYL) EPS by a Modest 2% - Leerink
August 29, 2016 10:08 AM
Mylan to launch generic EpiPen at half the price of original
August 29, 2016 6:28 AM
Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand
August 29, 2016 6:06 AM
Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product
August 29, 2016 6:00 AM
